Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27741919 | 1.00 | LMNA (0.55) | LMNAKDM4EADRB2ADRB1ADRB3 | |
| SCHEMBL28003757 | 0.86 | LMNA (0.58) | LMNAKDM4EADRB2ADRB1ADRB3 | |
| SCHEMBL25167208 | 0.85 | EPHX1 (0.47) | LMNAKDM4EADRB2ADRB1ADRB3 | |
| SCHEMBL966639 | 0.85 | EPHX1 (0.47) | LMNAKDM4EADRB2ADRB1ADRB3 | |
| SCHEMBL1345370 | 0.84 | LMNA (0.56) | LMNAKDM4EADRB2ADRB1ADRB3 | |
| SCHEMBL1345262 | 0.84 | LMNA (0.56) | LMNAKDM4EADRB2ADRB1ADRB3 | |
| SCHEMBL15456905 | 0.84 | LMNA (0.56) | LMNAKDM4EADRB2ADRB1ADRB3 | |
| SCHEMBL963917 | 0.83 | EPHX1 (0.46) | LMNAKDM4EADRB2ADRB1ADRB3 | |
| SCHEMBL966433 | 0.81 | MAPK1 (0.56) | LMNAKDM4EEPHX1CA12CA1 | |
| SCHEMBL301720 | 0.80 | LMNA (0.52) | LMNAKDM4EADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024329-B1 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2013-07-31 | — | — | EP | claimed |
| US-7868046-B2 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | DOMPE' PHA.R.MA S.P.A. (IT) | 2011-01-11 | — | — | US | claimed |
| US-20100152256-A1 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | DOMPE' PHA.R.MA S.P.A. (IT) | 2010-06-17 | — | — | US | claimed |
| US-7652169-B2 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | Dompe' Pha. R. Ma S.p.A. (IT) | 2010-01-26 | — | — | US | claimed |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | claimed |
| EP-2024329-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2009-02-18 | — | — | EP | claimed |
| WO-2007135080-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA. S.P.A. (IT) | 2007-11-29 | — | — | WO | claimed |
| US-11932683-B2 | Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets | NEW YORK UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230151081-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | UNIV NEW YORK (US) | 2023-05-18 | — | — | US | disclosed |
| US-11453715-B2 | Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets | NEW YORK UNIVERSITY (US) | 2022-09-27 | — | — | US | disclosed |
| EP-3848046-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A MUTATED LEUKOCIDIN E | New York University (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210009664-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | UNIV NEW YORK (US) | 2021-01-14 | — | — | US | disclosed |
| EP-3441474-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A MUTATED LEUKOCIDIN E | UNIV NEW YORK (US) | 2020-07-22 | — | — | EP | disclosed |
| US-7652169-B2 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | Dompe' Pha. R. Ma S.p.A. (IT) | 2010-01-26 | — | — | US | disclosed |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | disclosed |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | disclosed |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | disclosed |
| EP-2024329-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007135080-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA. S.P.A. (IT) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007135080-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA. S.P.A. (IT) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11453715-B2 | Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets | CXCR1, CXCR2, CXCR5 | LMNA 4124/4885KDM4E 4734/4885ADRB2 3402/4885 |
| US-20100152256-A1 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | CCR2, CXCR2, CXCR4 | LMNA 3868/4885KDM4E 2146/4885ADRB2 750/4885 |
| US-20230151081-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | CXCR1, CXCR2, CXCR5 | LMNA 4124/4885KDM4E 4734/4885ADRB2 3402/4885 |
| US-11932683-B2 | Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets | CXCR1, CXCR2, CXCR5 | LMNA 4124/4885KDM4E 4734/4885ADRB2 3402/4885 |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | CCR2, CXCR2, CXCR3 | LMNA 3833/4885KDM4E 2240/4885ADRB2 1127/4885 |
| US-20210009664-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | CXCR1, CXCR2, CXCR5 | LMNA 4124/4885KDM4E 4734/4885ADRB2 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.